Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension.
In this study of 27 untreated patients with uncomplicated essential hypertension, we report on elevated plasma levels of vascular endothelial growth factor and its soluble receptor Flt-1 compared with healthy controls; these increased levels are reduced by the treatment of hypertension. This raises the possibility that abnormal angiogenesis may contribute to the pathogenesis of complications related to hypertension and merits exploration in larger studies.
Belgore
F M
FM
University Department of Medicine, City Hospital, Birmingham, United Kingdom.
Blann
A D
AD
Li-Saw-Hee
F L
FL
Beevers
D G
DG
Lip
G Y
GY
D000959:Antihypertensive Agents / Q000627:therapeutic use; D004656:Enalapril / Q000627:therapeutic use; D016228:Endothelial Growth Factors / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D019808:Losartan / Q000627:therapeutic use; D008222:Lymphokines / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D011518:Proto-Oncogene Proteins / Q000097:blood*; D020794:Receptor Protein-Tyrosine Kinases / Q000097:blood*; D017978:Receptors, Growth Factor / Q000097:blood*; D042461:Vascular Endothelial Growth Factor A; D040281:Vascular Endothelial Growth Factor Receptor-1; D042442:Vascular Endothelial Growth Factors
D000959:Antihypertensive Agents; D016228:Endothelial Growth Factors; D008222:Lymphokines; D011518:Proto-Oncogene Proteins; D017978:Receptors, Growth Factor; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D004656:Enalapril; D020794:Receptor Protein-Tyrosine Kinases; D040281:Vascular Endothelial Growth Factor Receptor-1; D019808:Losartan